D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 93 Citations 36,683 370 World Ranking 5199 National Ranking 223

Research.com Recognitions

Awards & Achievements

2011 - Fellow of the Royal Society of Canada Academy of Science

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Surgery

His primary areas of investigation include Internal medicine, Gastroenterology, Placebo, Surgery and Crohn's disease. His Internal medicine study which covers Immunology that intersects with Microbiology. His Gastroenterology study incorporates themes from Larazotide, Chemotherapy, Certolizumab pegol, Gluten free and Corticosteroid.

The various areas that he examines in his Placebo study include Crohn's Disease Activity Index, Etrolizumab, Gastrointestinal agent and Infliximab. His work deals with themes such as Vedolizumab, Adalimumab and Pharmacokinetics, which intersect with Surgery. His Crohn's disease research is multidisciplinary, relying on both Methotrexate, Anemia, Randomization and Prednisone.

His most cited work include:

  • Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (1693 citations)
  • Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (1487 citations)
  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial (1331 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Inflammatory bowel disease, Crohn's disease and Ulcerative colitis. His Internal medicine study incorporates themes from Placebo, Endocrinology and Surgery. His Surgery study focuses on Randomized controlled trial in particular.

His Gastroenterology research is multidisciplinary, incorporating elements of Feces, Urine, Adverse effect and Certolizumab pegol. His work in Inflammatory bowel disease covers topics such as Immunology which are related to areas like Microbiology. His Infliximab research incorporates themes from Gastrointestinal agent, Adalimumab, Maintenance therapy and Retrospective cohort study.

He most often published in these fields:

  • Internal medicine (60.94%)
  • Gastroenterology (40.19%)
  • Inflammatory bowel disease (26.98%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (60.94%)
  • Gastroenterology (40.19%)
  • Ulcerative colitis (18.68%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Gastroenterology, Ulcerative colitis, Crohn's disease and Inflammatory bowel disease. He has researched Internal medicine in several fields, including Surgery and Oncology. His study ties his expertise on Immunology together with the subject of Gastroenterology.

His work investigates the relationship between Ulcerative colitis and topics such as Randomized controlled trial that intersect with problems in Observational study, Physical therapy and Placebo. His Crohn's disease research incorporates elements of Cross-sectional study, Mediterranean diet and Moderate to severe. His work deals with themes such as Breastfeeding and Intensive care medicine, which intersect with Inflammatory bowel disease.

Between 2015 and 2021, his most popular works were:

  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection (139 citations)
  • Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD (137 citations)
  • An overview of clinical decision support systems: benefits, risks, and strategies for success. (101 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Richard N. Fedorak mainly investigates Internal medicine, Crohn's disease, Infliximab, Ulcerative colitis and Gastroenterology. The study incorporates disciplines such as Clostridium difficile and Immunology in addition to Internal medicine. His Crohn's disease research includes elements of Inflammatory bowel disease and Abdominal surgery.

His studies deal with areas such as Gastrointestinal agent and Adalimumab as well as Infliximab. The various areas that Richard N. Fedorak examines in his Ulcerative colitis study include Tolerability, Immune system and Intensive care medicine. The concepts of his Gastroenterology study are interwoven with issues in Immunohistochemistry, Intestinal mucosa, Staining, Stain and Biopsy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey.
The New England Journal of Medicine (2004)

2385 Citations

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak.
Gastroenterology (2006)

1831 Citations

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)

1648 Citations

Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak.
Gut (2007)

1139 Citations

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Brian G Feagan;Gordon R Greenberg;Gary Wild;Richard N Fedorak.
The New England Journal of Medicine (2005)

984 Citations

Methotrexate for the Treatment of Crohn's Disease

B G Feagan;J Rochon;R N Fedorak;E J Irvine.
The New England Journal of Medicine (1995)

922 Citations

Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Karen L. Madsen;Jason S. Doyle;Laurence D. Jewell;Michele M. Tavernini.
Gastroenterology (1999)

918 Citations

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

B G Feagan;R N Fedorak;E J Irvine;G Wild.
The New England Journal of Medicine (2000)

897 Citations

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

Rodrigo Bibiloni;Richard N Fedorak;Gerald W Tannock;Karen L Madsen.
The American Journal of Gastroenterology (2005)

844 Citations

The epidemiology of inflammatory bowel disease in Canada : A population-based study

Charles N Bernstein;Andre Wajda;Lawrence W Svenson;Adrian MacKenzie.
The American Journal of Gastroenterology (2006)

725 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Richard N. Fedorak

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 322

Brian G. Feagan

Brian G. Feagan

University of Western Ontario

Publications: 223

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 213

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 197

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 177

Silvio Danese

Silvio Danese

Humanitas University

Publications: 167

Paul Rutgeerts

Paul Rutgeerts

KU Leuven

Publications: 155

Stephen B. Hanauer

Stephen B. Hanauer

Northwestern University

Publications: 145

Remo Panaccione

Remo Panaccione

University of Calgary

Publications: 126

Edward V. Loftus

Edward V. Loftus

Mayo Clinic

Publications: 115

Charles N. Bernstein

Charles N. Bernstein

University of Manitoba

Publications: 113

Javier P. Gisbert

Javier P. Gisbert

Autonomous University of Madrid

Publications: 113

Walter Reinisch

Walter Reinisch

Medical University of Vienna

Publications: 112

Markus F. Neurath

Markus F. Neurath

University of Erlangen-Nuremberg

Publications: 108

Geert R. D'Haens

Geert R. D'Haens

University of Amsterdam

Publications: 103

Bruce E. Sands

Bruce E. Sands

Icahn School of Medicine at Mount Sinai

Publications: 101

Something went wrong. Please try again later.